18th Aug 2009 07:00
Vectura Group plc
Interim Management Statement
Chippenham, UK - 18 August 2009: Vectura Group plc (LSE: VEC) ("Vectura"), today publishes its Interim Management Statement for the period from 1 April 2009 to date.
Highlights
Financial outlook
Dr Chris Blackwell, Chief Executive of Vectura, commented:
"We have continued to make good progress with our clinical pipeline whilst maintaining our strong financial position. With Phase III trials expected to start later this year for QVA149, which has the potential to be the first once-daily LAMA/LABA combination available to patients, and our other in-house clinical programmes expected to yield results in 2010, we have important newsflow ahead and remain very confident of Vectura's prospects."
- Ends -
Enquiries:
|
Vectura Group plc |
+44 (0)1249 667700 |
|
Chris Blackwell, Chief Executive |
|
|
Anne Hyland, Chief Financial Officer |
|
|
Julia Wilson, Director of Investor Relations |
|
|
Financial Dynamics |
+44 (0)20 7831 3113 |
|
Ben Atwell |
|
|
Susan Quigley |
Notes for Editors:
About Vectura
Vectura Group plc is a product focused Group developing inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD); a growing market currently estimated to be worth $20 billion. Vectura also develops products for other lung pathologies and non-respiratory diseases.
Vectura has eight products marketed by its partners, and a portfolio of drugs in clinical and pre-clinical development, some of which have been licensed to major pharmaceutical companies. Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.
Vectura has development collaborations with several pharmaceutical companies, including Boehringer Ingelheim, Novartis, Sandoz (the generics arm of Novartis), Baxter, GlaxoSmithKline (GSK), Mylan, UCB and Otsuka. Vectura has been included in the FTSE 250 index since 23 March 2009. For further information, please visit Vectura's website at www.vectura.com
Forward-Looking Statements
This press release contains "forward-looking statements", including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Related Shares:
VEC.L